Genyova is a fixed-dose combination tablet containing cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide, according to an FDA statement.
“Today’s approval of a fixed dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection,” Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, said in a statement.
The FDA evaluated the treatment’s safety and efficacy in 3,171 patients and results showed it was effective in reducing viral loads compared to other FDA-approved treatments. The drug carries a boxed warning alerting patients and providers it can cause both a buildup of lactic acid in the blood and severe liver problems. These problems can be fatal, but the most significant side effect associated with Genvoya was nausea.
More articles on infection control:
3 elements every C. diff management program should include
The invisible force behind 2,000 layoffs this year? Microbes
CDC: Gonorrhea becoming more resistant to one antibiotic
